For the first time, the Federal Drug Administration (FDA) has approved a medication for the treatment of non-metastatic castration-resistant prostate cancer (CRPC). Apalutimide , the new drug is based on the results of the Phase 3 SPARTAN clinical trial which was sponsored by Janssen .